SPRC (Clearmind Medicine) Rentabilitas dodolan miturut bathi reged

Simbol resmi perusahaan Clearmind Medicine (SPRC)

Israeli business SciSparc Ltd (SPRC) utilizes outsourcing to reduce costs while expanding its CNS drug portfolio, ranging from Alzheimer's disease to Tourette syndrome. The gross margin trend on this GURU.Markets chart clearly demonstrates operational profitability, where the 51.20 metric reflects current dynamics. The development of unique autism treatments creates potential for long-term patent revenue.

SPRC Rentabilitas reged SciSparc Corp (21.02.2024 - 20.11.2026)

Rincian analitis lan laporan data perusahaan SciSparc Ltd (SPRC)

- rega lan prakiraan konsensus rega:
Pambiji fundamental:SPRC, Clearmind Medicine
Produk asil prodhuksi SciSparc Corp

Investors use this indicator to evaluate the efficiency of direct cost management and determine the business's operational resilience threshold. The metric is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, measuring the profit margin before deducting administrative expenses. Analysis of the gross trading margin confirms the effectiveness of the SciSparc Ltd. (SPRC) model, where outsourcing testing while retaining patent rights minimizes capital expenditures.